NCT01510860View on ClinicalTrials.gov

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Primary Biliary Cirrhosis
Interventions
DRUG

UDCA (Ursodeoxycholic acid)

250 mg

DRUG

UDCA (Ursodeoxycholic acid)

500 mg

Trial Locations (1)

81377

Klinikum Grosshadern, Munich

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY